Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 19;jclinpath-2020-206711.
doi: 10.1136/jclinpath-2020-206711. Online ahead of print.

Predictive Molecular Pathology in the Time of COVID-19

Affiliations
Free PMC article

Predictive Molecular Pathology in the Time of COVID-19

Umberto Malapelle et al. J Clin Pathol. .
Free PMC article

Abstract

Aims: In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified.

Methods: The organisation of the University of Naples Federico II predictive pathology laboratory was assessed before (March-April 2019) and during (March-April 2020) the Italian lockdown.

Results: The number of patients undergoing single or multiple biomarker testing was similar in 2019 (n=43) and in 2020 (n=45). Considering adequate samples for molecular testing, before the outbreak, next-generation sequencing was mostly used (35/42, 83.3%). Testing six genes had a reagent cost of €98/patient. Conversely, in 2020, almost all cases (38/41, 92.7%) were analysed by automated testing. This latter had for any single assay/gene a significant reagent cost (€95-€136) and a faster mean turnaround time (5.3 vs 7.9 working days).

Conclusion: In the times of coronavirus, laboratory fully automated platforms simplify predictive molecular testing. Laboratory staff may be more safely and cost-effectively managed.

Keywords: laboratory personnel; medical oncology; pathology, molecular.

Conflict of interest statement

Competing interests: UM reports personal fees (as speaker bureau or advisor) from Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck and BMS. GT reports personal fees (as speaker bureau or advisor) from Roche, MSD and Pfizer.

Figures

Figure 1
Figure 1
Molecular biology technologies pre-COVID-19 and during the COVID-19 outspread. With respect to 2019, during the COVID-19 outbreak, almost all cases were analysed by automated testing (Idylla), with a reduction of turnaround time (5.3 vs 7.9 working days). NGS, next-generation sequencing; TAT, turnaround time.

Similar articles

See all similar articles

References

    1. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470–3. 10.1016/S0140-6736(20)30185-9 - DOI - PMC - PubMed
    1. World Health Organization (WHO) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11, 2020. Available: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19-11-march-2020
    1. World Health Organization (WHO) Coronavirus disease (COVID‐2019) situation reports, 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports [Accessed 21 Apr 2020].
    1. Government of Italy Decree of the President of the Council of ministers March 9th, 2020. Available: https://www.gazzettaufficiale.it/eli/id/2020/03/09/20A01558/sg
    1. Vigliar E, Malapelle U, Iaccarino A, et al. Pd-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. J Clin Pathol 2019;72:412–7. 10.1136/jclinpath-2019-205732 - DOI - PubMed

LinkOut - more resources

Feedback